Advertisement

Drugs

, Volume 70, Issue 16, pp 2073–2088 | Cite as

Dienogest

A Review of its Use in the Treatment of Endometriosis
  • Paul L. McCormack
Adis Drug Evaluation

Abstract

Dienogest (Visanne®) is a synthetic oral progestogen with unique pharmacological properties that is indicated at a dosage of 2mg/day for the treatment of endometriosis. It is generally highly selective for the progesterone receptor and displays strong progestational effects and moderate antigonadotrophic effects, but no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest has moderate affinity for progesterone receptors (10% that of progesterone) and at a dosage of 2mg/day only moderately suppresses estradiol levels. It has high oral bioavailability and a half-life suitable for once-daily administration.

In randomized clinical trials, oral dienogest was significantly more effective than placebo in reducing pelvic pain in patients with confirmed endometriosis. In trials comparing oral dienogest for 16 or 24 weeks with gonadotropin-releasing hormone (GnRH) agonists commonly used in the treatment of endometriosis, dienogest was noninferior to depot leuprorelin in reducing pelvic pain and was not significantly different from intranasal buserelin and depot triptorelin in improving combined symptoms/signs scores or revised American Fertility Society (rAFS) staging scores, respectively. Improvements were also noted in some measures of health-related quality of life. The efficacy of dienogest was sustained during long-term treatment for more than 1 year. Dienogest was generally well tolerated and was not considered to be associated with clinically relevant androgenic effects. It appeared to have fewer hypoestrogenic effects than the GnRH agonists. Dienogest was associated with a high incidence of abnormal menstrual bleeding patterns, although this was generally well tolerated by patients, with few discontinuing therapy, and the bleeding intensity and frequency decreased over time. Therefore, oral dienogest offers an effective, generally well tolerated therapeutic option for the long-term treatment of endometriosis.

Keywords

Bone Mineral Density Endometriosis GnRH Agonist Leuprorelin Combine Oral Contraceptive 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005 Oct; 20(10): 2698–704PubMedCrossRefGoogle Scholar
  2. 2.
    Bulun SE. Endometriosis. N Engl J Med 2009 Jan 15; 360(3): 268–79PubMedCrossRefGoogle Scholar
  3. 3.
    Giudice LC. Endometriosis. N Engl J Med 2010 Jun 24; 362(25): 2389–98PubMedCrossRefGoogle Scholar
  4. 4.
    World Endometriosis Research Foundation [online]. Available from URL: http://www.endometriosisfoundation.org/ [Accessed 2010 Oct 1]
  5. 5.
    European network on endometriosis [online]. Available from URL: http://www.endonetwork.eu/ [Accessed 2010 Oct 1]
  6. 6.
    European Society of Human Reproduction and Embryology. ESHRE guideline for the diagnosis and treatment of endometriosis (online update 2007 Jun) [online]. Available from URL: http://guidelines.endometriosis.org/index.html [Accessed 2010 Oct 1]
  7. 7.
    Royal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis (Green-top guideline no. 24). 2006 Oct [online]. Available from URL: http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT24InvestigationEndometriosis2006.pdf [Accessed 2010 Oct 1]
  8. 8.
    Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009; 69(6): 649–75PubMedCrossRefGoogle Scholar
  9. 9.
    Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995; 31: 517–36Google Scholar
  10. 10.
    Köhler G, Göretzlehner G, Amon I. Therapy of endometriosis with dienogest [in German]. Zentralbl Gynakol 1987; 109(12): 795–801PubMedGoogle Scholar
  11. 11.
    Foster RH, Wilde MI. Dienogest. Drugs 1998 Nov; 56(5): 825–33; discussion 834-5PubMedCrossRefGoogle Scholar
  12. 12.
    Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008 Feb; 73(2): 222–31PubMedCrossRefGoogle Scholar
  13. 13.
    Mochida Pharmaceutical Co. Ltd. Drug interview form: DINagest Tab. 1 mg (dienogest film-coated tablets) for the treatment of endometriosis. 2007 Dec, 1–82Google Scholar
  14. 14.
    Medicines Evaluation Board (Netherlands). Public assessment report of the Medicines Evaluation Board in the Netherlands: Visanne (dienogest), tablets, 2mg. 2010 Mar [online]. Available from URL: http://db.cbg-meb.nl/Pars/h104058.pdf [Accessed 2010 Oct 1]
  15. 15.
    Moore C, Carol W, Gräser T, et al. Influence of dienogest on ovulation in young fertile women. Clin Drug Investig 1999; 18(4): 271–8CrossRefGoogle Scholar
  16. 16.
    Klipping C, Duijkers I, Faustmann S, et al. Pharmacodynamic study of four oral dosages of dienogest [abstract no. P-304]. Fertil Steril 2010 Sep; 94 (4 Suppl. 1): S181CrossRefGoogle Scholar
  17. 17.
    Medicines Evaluation Board (Netherlands). Visanne® (dienogest 2mg tablet): summary of product characteristics [online]. Available from URL: http://db.cbg-meb.nl/IB-teksten/h104058.pdf [Accessed 2010 Oct 1]
  18. 18.
    Strowitzki T, Faustmann T, Gerlinger C, et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010 Aug; 151(2): 193–8PubMedCrossRefGoogle Scholar
  19. 19.
    Momoeda M, Taketani Y. A randomized, double-blind, multicenter, parallel, dose-response study of dienogest in patients with endometriosis [in Japanese]. J Pharmacol Ther 2007; 35: 769–83Google Scholar
  20. 20.
    Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 2009 Dec; 35(6): 1069–76PubMedCrossRefGoogle Scholar
  21. 21.
    Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, double-blind, multicenter, controlled trial. Fertil Steril 2009 Mar; 91(3): 675–81PubMedCrossRefGoogle Scholar
  22. 22.
    Schindler AE, Christensen B, Henkel A, et al. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol Endocrinol 2006 Jan; 22(1): 9–17PubMedCrossRefGoogle Scholar
  23. 23.
    Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010 Mar; 25(3): 633–41PubMedCrossRefGoogle Scholar
  24. 24.
    Katsuki Y, Takano Y, Futamura Y, et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 1998 Feb; 138(2): 216–26PubMedCrossRefGoogle Scholar
  25. 25.
    Shimizu Y, Takeuchi T, Mita S, et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 2009 Oct; 15(10): 693–701PubMedCrossRefGoogle Scholar
  26. 26.
    Nakamura M, Katsuki Y, Shibutani Y, et al. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 1999 Dec 10; 386(1): 33–40PubMedCrossRefGoogle Scholar
  27. 27.
    Katayama H, Katayama T, Uematsu K, et al. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod. Epub 2010 Sep 2Google Scholar
  28. 28.
    Köhler G, Lembke S, Brachmann K, et al. Behavior of parameters of liver metabolism in intermediate-term use of the gestagen dienogest in the treatment of endometriosis [in German]. Zentralbl Gynakol 1989; 111(12): 807–10PubMedGoogle Scholar
  29. 29.
    Köhler G, Göretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 1989; 68(7): 633–5PubMedCrossRefGoogle Scholar
  30. 30.
    Nikschick S, Köhler G, Männchen E. Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest. Exp Clin Endocrinol 1989 Sep; 94(1–2): 211–4PubMedGoogle Scholar
  31. 31.
    Köhler G, Faustmann TA, Gerlinger C, et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010 Jan; 108(1): 21–5PubMedCrossRefGoogle Scholar
  32. 32.
    Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002 Apr; 77(4): 684–92PubMedCrossRefGoogle Scholar
  33. 33.
    Seitz C, Faustmann T, Gerlinger C, et al. Long-term experience with dienogest for the treatment of endometriosis: a one-year, open-label, follow-up study [abstract no. O835]. Int J Gynecol Obstet 2009; 107 Suppl. 2: S332CrossRefGoogle Scholar
  34. 34.
    Gerlinger C, Schmitz H, Schumacher U, et al. Minimally clinically important difference for the endometriosis associated pelvic pain measured on a visual analogue scale [abstract no. 0341]. Int J Gynecol Obstet 2009; 107 Suppl. 2: S190CrossRefGoogle Scholar
  35. 35.
    Knight C, Colligs A, Lipinski J. A budget impact analysis of dienogest in treating endometriosis associated pelvic pain in Germany [abstract no. PIH8]. Value Health 2009 Oct; 12(7): A 291. Plus poster presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24–27; ParisCrossRefGoogle Scholar
  36. 36.
    Irahara M, Harada T, Momoeda M, et al. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 2007; 6(4): 223–8CrossRefGoogle Scholar
  37. 37.
    Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986 Sep; 34(3): 253–60PubMedCrossRefGoogle Scholar
  38. 38.
    Australian Government: Department of Health and Ageing Therapeutic Goods Administration. Australian Public Assessment Report for dienogest. 2010 Sep [online]. Available from URL: http://www.tga.gov.au/pmeds/auspar/auspar-visanne.pdf [Accessed 2010 Oct 1]
  39. 39.
    Seitz C, Gerlinger C, Faustmann T, et al. Safety of dienogest in the long-term treatment of endometriosis: a one-year, open-label, follow-up study [abstract no. P-66]. Fertil Steril 2009; 92(3): S107CrossRefGoogle Scholar
  40. 40.
    Schindler AE, Henkel A, Moore C, et al. Effect and safety of high-dose dienogest (20mg/day) in the treatment of women with endometriosis. Arch Gynecol Obstet. Epub 2009 Dec 15Google Scholar
  41. 41.
    Australian Government: Department of Health and Ageing Therapeutic Goods Administration. Advisory Committee on Prescription Medicines 269th meeting recommendations. 2010 Apr [online]. Available from URL: http://www.tga.gov.au/committee/acpm/acpm0269.htm [Accessed 2010 Oct 1]
  42. 42.
    Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2008 Nov; 90 Suppl. 3: S260–9Google Scholar
  43. 43.
    Sinaii N, Plumb K, Cotton L, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril 2008 Mar; 89(3): 538–45PubMedCrossRefGoogle Scholar
  44. 44.
    Davis L, Kennedy SS, Moore J, et al. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2009; (1): CD001019Google Scholar
  45. 45.
    Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008 Nov; 90(5): 1583–8PubMedCrossRefGoogle Scholar
  46. 46.
    Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993 Jul; 60(1): 75–9PubMedGoogle Scholar
  47. 47.
    Selak V, Farquhar C, Prentice A, et al. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2007; (4): CD000068Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore, AucklandNew Zealand

Personalised recommendations